562 related articles for article (PubMed ID: 22461535)
1. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease.
Vlassara H; Uribarri J; Cai W; Goodman S; Pyzik R; Post J; Grosjean F; Woodward M; Striker GE
Clin J Am Soc Nephrol; 2012 Jun; 7(6):934-42. PubMed ID: 22461535
[TBL] [Abstract][Full Text] [Related]
2. Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease.
Yubero-Serrano EM; Woodward M; Poretsky L; Vlassara H; Striker GE;
Clin J Am Soc Nephrol; 2015 May; 10(5):759-66. PubMed ID: 25710801
[TBL] [Abstract][Full Text] [Related]
3. Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease.
Rastogi A
Ther Adv Cardiovasc Dis; 2013 Dec; 7(6):322-42. PubMed ID: 24327730
[TBL] [Abstract][Full Text] [Related]
4. Comparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis.
Chennasamudram SP; Noor T; Vasylyeva TL
J Ren Care; 2013 Jun; 39(2):82-9. PubMed ID: 23574727
[TBL] [Abstract][Full Text] [Related]
5. Managing chronic inflammation in the aging diabetic patient with CKD by diet or sevelamer carbonate: a modern paradigm shift.
Vlassara H; Cai W; Chen X; Serrano EJ; Shobha MS; Uribarri J; Woodward M; Striker GE
J Gerontol A Biol Sci Med Sci; 2012 Dec; 67(12):1410-6. PubMed ID: 23109677
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis.
Ketteler M; Rix M; Fan S; Pritchard N; Oestergaard O; Chasan-Taber S; Heaton J; Duggal A; Kalra PA
Clin J Am Soc Nephrol; 2008 Jul; 3(4):1125-30. PubMed ID: 18450923
[TBL] [Abstract][Full Text] [Related]
7. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
[TBL] [Abstract][Full Text] [Related]
8. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients.
Kakuta T; Tanaka R; Hyodo T; Suzuki H; Kanai G; Nagaoka M; Takahashi H; Hirawa N; Oogushi Y; Miyata T; Kobayashi H; Fukagawa M; Saito A
Am J Kidney Dis; 2011 Mar; 57(3):422-31. PubMed ID: 21239096
[TBL] [Abstract][Full Text] [Related]
9. Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD.
Liabeuf S; Ryckelynck JP; El Esper N; Ureña P; Combe C; Dussol B; Fouque D; Vanhille P; Frimat L; Thervet E; Mentaverri R; Prié D; Choukroun G;
Clin J Am Soc Nephrol; 2017 Dec; 12(12):1930-1940. PubMed ID: 29074818
[TBL] [Abstract][Full Text] [Related]
10. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis.
Takei T; Otsubo S; Uchida K; Matsugami K; Mimuro T; Kabaya T; Akiba T; Nitta K
Nephron Clin Pract; 2008; 108(4):c278-83. PubMed ID: 18434749
[TBL] [Abstract][Full Text] [Related]
11. [Either calcium carbonate or sevelamer decreases urinary oxalate excretion in chronic renal failure patients].
Caravaca F; Ruiz AB; Escola JM; Hernández Gallego R; Cerezo I; Fernández N; Barroso S; Martín MV
Nefrologia; 2007; 27(4):466-71. PubMed ID: 17944584
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
Prajapati VA; Galani VJ; Shah PR
Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial.
Bleskestad IH; Bergrem H; Hartmann A; Godang K; Gøransson LG
BMC Nephrol; 2012 Jun; 13():49. PubMed ID: 22742720
[TBL] [Abstract][Full Text] [Related]
14. Mortality in kidney disease patients treated with phosphate binders: a randomized study.
Di Iorio B; Bellasi A; Russo D;
Clin J Am Soc Nephrol; 2012 Mar; 7(3):487-93. PubMed ID: 22241819
[TBL] [Abstract][Full Text] [Related]
15. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
[TBL] [Abstract][Full Text] [Related]
16. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
Chen N; Wu X; Ding X; Mei C; Fu P; Jiang G; Li X; Chen J; Liu B; La Y; Hou F; Ni Z; Fu J; Xing C; Yu X; Huang C; Zuo L; Wang L; Hunter J; Dillon M; Plone M; Neylan J
Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis.
Delmez J; Block G; Robertson J; Chasan-Taber S; Blair A; Dillon M; Bleyer AJ
Clin Nephrol; 2007 Dec; 68(6):386-91. PubMed ID: 18184521
[TBL] [Abstract][Full Text] [Related]
18. Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial.
Ruggiero B; Trillini M; Tartaglione L; Rotondi S; Perticucci E; Tripepi R; Aparicio C; Lecchi V; Perna A; Peraro F; Villa D; Ferrari S; Cannata A; Mazzaferro S; Mallamaci F; Zoccali C; Bellasi A; Cozzolino M; Remuzzi G; Ruggenenti P; Kohan DE;
Am J Kidney Dis; 2019 Sep; 74(3):338-350. PubMed ID: 31027883
[TBL] [Abstract][Full Text] [Related]
19. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial.
Yilmaz MI; Sonmez A; Saglam M; Yaman H; Kilic S; Eyileten T; Caglar K; Oguz Y; Vural A; Yenicesu M; Mallamaci F; Zoccali C
Am J Kidney Dis; 2012 Feb; 59(2):177-85. PubMed ID: 22137672
[TBL] [Abstract][Full Text] [Related]
20. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
